Abstract
Ischemic metabolism in the enterogram is a crucial issue of clinical concern for deep understanding of drug delivery. In this study we use nanochemistry in micelle to produce the nanocarrier of erythropoietin (EPO) and traced the metabolizable process of the EPO carrier in vivo. Nascence Sprague-Dawley rats of 5 days are treated with EPO-loading nanocarriers. Curative effects of the EPO nanocarriers for periventricular leukomalacia (PVL) models are validated by the analysis of pathology and praxiology of the mice. We demonstrate in vivo that EPO nanocarriers can ameliorate drug-induced liquefaction caused by hypoxia. By tracking the metabolism of EPO in liver and kidney, we suggest that nanocarriers effectively prolong the metabolic half-life and clearance time of EPO. HPLC results show that exciting amino acid toxicity was inhibited, since mobilization of late oligodendrocyte can be protected by treatment of EPO vehicles from hypoxia.